Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics

András Perényi, G. Bagdy, Mihály Arató, Ede Frecska

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neuroleptic treatment was instituted in 20 female schizophrenic patients, who had not received neuroleptics for at least the preceding 3 months. Both the therapeutic response to neuroleptics and the development of parkinsonian side effects were monitored in these patients. In addition, plasma dopamine-β-hydroxylase (DBH) and platelet monoamine oxidase (MAO) activities were measured. None of the neuroleptic responders developed parkinsonian symptoms. During the course of the 28-day treatment, there was a significant decrease in platelet MAO activity. There was a tendency for responders without parkinsonian symptoms to have lower plasma DBH activity than did nonresponders with parkinsonian symptoms.

Original languageEnglish
Pages (from-to)119-127
Number of pages9
JournalPsychiatry Research
Volume13
Issue number2
DOIs
Publication statusPublished - 1984

Fingerprint

Antipsychotic Agents
Biomarkers
Monoamine Oxidase
Blood Platelets
Mixed Function Oxygenases
Dopamine
Therapeutics
Clinical Studies

Keywords

  • dopamine-β-hydroxylase
  • monoamine oxidase
  • Neuroleptics
  • therapeutic response neuroleptic-induced parkinsonism

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics. / Perényi, András; Bagdy, G.; Arató, Mihály; Frecska, Ede.

In: Psychiatry Research, Vol. 13, No. 2, 1984, p. 119-127.

Research output: Contribution to journalArticle

Perényi, András ; Bagdy, G. ; Arató, Mihály ; Frecska, Ede. / Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics. In: Psychiatry Research. 1984 ; Vol. 13, No. 2. pp. 119-127.
@article{650f907a690d4dcd9d88cdcf25930551,
title = "Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics",
abstract = "Neuroleptic treatment was instituted in 20 female schizophrenic patients, who had not received neuroleptics for at least the preceding 3 months. Both the therapeutic response to neuroleptics and the development of parkinsonian side effects were monitored in these patients. In addition, plasma dopamine-β-hydroxylase (DBH) and platelet monoamine oxidase (MAO) activities were measured. None of the neuroleptic responders developed parkinsonian symptoms. During the course of the 28-day treatment, there was a significant decrease in platelet MAO activity. There was a tendency for responders without parkinsonian symptoms to have lower plasma DBH activity than did nonresponders with parkinsonian symptoms.",
keywords = "dopamine-β-hydroxylase, monoamine oxidase, Neuroleptics, therapeutic response neuroleptic-induced parkinsonism",
author = "Andr{\'a}s Per{\'e}nyi and G. Bagdy and Mih{\'a}ly Arat{\'o} and Ede Frecska",
year = "1984",
doi = "10.1016/0165-1781(84)90055-6",
language = "English",
volume = "13",
pages = "119--127",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics

AU - Perényi, András

AU - Bagdy, G.

AU - Arató, Mihály

AU - Frecska, Ede

PY - 1984

Y1 - 1984

N2 - Neuroleptic treatment was instituted in 20 female schizophrenic patients, who had not received neuroleptics for at least the preceding 3 months. Both the therapeutic response to neuroleptics and the development of parkinsonian side effects were monitored in these patients. In addition, plasma dopamine-β-hydroxylase (DBH) and platelet monoamine oxidase (MAO) activities were measured. None of the neuroleptic responders developed parkinsonian symptoms. During the course of the 28-day treatment, there was a significant decrease in platelet MAO activity. There was a tendency for responders without parkinsonian symptoms to have lower plasma DBH activity than did nonresponders with parkinsonian symptoms.

AB - Neuroleptic treatment was instituted in 20 female schizophrenic patients, who had not received neuroleptics for at least the preceding 3 months. Both the therapeutic response to neuroleptics and the development of parkinsonian side effects were monitored in these patients. In addition, plasma dopamine-β-hydroxylase (DBH) and platelet monoamine oxidase (MAO) activities were measured. None of the neuroleptic responders developed parkinsonian symptoms. During the course of the 28-day treatment, there was a significant decrease in platelet MAO activity. There was a tendency for responders without parkinsonian symptoms to have lower plasma DBH activity than did nonresponders with parkinsonian symptoms.

KW - dopamine-β-hydroxylase

KW - monoamine oxidase

KW - Neuroleptics

KW - therapeutic response neuroleptic-induced parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=0021680823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021680823&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(84)90055-6

DO - 10.1016/0165-1781(84)90055-6

M3 - Article

C2 - 6151713

AN - SCOPUS:0021680823

VL - 13

SP - 119

EP - 127

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2

ER -